GlassScriptPhysician profile
Sharon Weiya Lei
NPI 1407524119
$3,068.10
in general payments reported to CMS, 2019-2025
15 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $239 · 2022: $642 · 2023: $236 · 2024: $595 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,187.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $654.05 | 2024-2025 | Xiidra, Miebo |
| Alcon Vision LLC | $532.00 | 2023-2025 | Rocklatan, Tryptyr, Eysuvis |
| Amgen INC. | $366.88 | 2024-2025 | Tepezza |
| Dompe US, INC. | $216.94 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $209.10 | 2022-2025 | Tyrvaya |
| Horizon Therapeutics Plc | $208.42 | 2022-2023 | Tepezza |
| Astellas Pharma US INC | $146.57 | 2023 | |
| Ivantis, INC | $135.39 | 2021 | |
| Sight Sciences, INC. | $129.70 | 2024 | Omni Surgical System |
| Kala Pharmaceuticals, INC. | $124.99 | 2022 | |
| Allergan, INC. | $114.52 | 2022 | |
| Synergeyes, INC. | $86.65 | 2021 | |
| Astellas Pharma Global Development | $81.65 | 2024 | Izervay |
| Sun Pharmaceutical Industries INC. | $46.11 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $15.13 | 2025 | Tecnis Iol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Lei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.